Literature DB >> 16353206

Clinical trial accrual among new cancer patients at a community-based cancer center.

Ronald S Go1, Kathleen A Frisby, Jennifer A Lee, Michelle A Mathiason, Christine M Meyer, Jodi L Ostern, Sara M Walther, Jonean E Schroeder, Lori A Meyer, Kathryn E Umberger.   

Abstract

BACKGROUND: To the authors' knowledge, only limited data are available regarding clinical trial accrual patterns and the barriers encountered among newly diagnosed patients seen at community-based cancer centers.
METHODS: In the current study, the authors prospectively collected clinical and sociodemographic data from all adult patients seen at a community-based cancer center who had new cancers diagnosed between 2003-2004. Clinical trial enrollment decisions were noted and factors that prevented accrual were identified.
RESULTS: There was a total of 1012 new cancer patients. In 587 patients (58%), clinical trials appropriate for the diagnosis and stage of disease were not available. Among those patients for whom trials were available, 19.8% did not meet eligibility criteria, and only 9.9% of patients were enrolled. Although more trials were found to be available for women compared with men (51% vs. 32%; P < 0.01), the accrual rates were equal (11.2% vs. 7.6%; P = 0.24). Elderly patients comprised approximately 59.4% of those patients with available trials, but they were less likely to be enrolled (5.1% vs. 16.8%; P < 0.01). The major barriers to nonparticipation can be grouped into protocol limitations (68.1%), physician triage (16%), and patient decisions (15.9%). The overall accrual rate when all patients were included was 4% (42 of 1012 patients).
CONCLUSIONS: At the study institution, participation in clinical trials is reported to be low. The unavailability of appropriate clinical trials represents the most significant barrier. Continuing efforts to encourage physicians and to educate patients remain necessary. If the current study findings are found to be applicable to other community-based cancer centers, making a larger variety of clinical trials available to the community may help to improve the accrual of patients to national cancer clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16353206     DOI: 10.1002/cncr.21597

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  52 in total

1.  A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles.

Authors:  Eric B Lynam; Jiin Leaw; Matthew B Wiener
Journal:  Drug Inf J       Date:  2012-07

2.  Barriers to Cancer Clinical Trial Participation Among Saudi Nationals: A Cross-Sectional Study.

Authors:  Khalid M Almutairi; Wadi B Alonazi; Abdulaziz A Alodhayani; Jason M Vinluan; Mahaman Moussa; Abdulrahman S Al-Ajlan; Khalid Alsaleh; Duna Alruwaimi; Nader E Alotaibi
Journal:  J Relig Health       Date:  2017-04

3.  Barriers to recruitment of rural patients in cancer clinical trials.

Authors:  Shamsuddin Virani; Lola Burke; Scot C Remick; Jame Abraham
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial.

Authors:  Chiharu Tanai; Takako Eguchi Nakajima; Kengo Nagashima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kei Muro; Kuniaki Shirao; Hideo Kunitoh; Yasuhiro Matsumura; Seiichiro Yamamoto; Yasuhiro Shimada
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

5.  A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program.

Authors:  Julian W Proctor; Elaine Martz; Larry L Schenken; Rebecca Rainville; Ursula Marlowe
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

6.  Improving clinical trial accrual by streamlining the referral process.

Authors:  Lawrence B Afrin; James C Oates; Diane L Kamen
Journal:  Int J Med Inform       Date:  2014-09-16       Impact factor: 4.046

Review 7.  Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Authors:  Saiama N Waqar; Philip D Bonomi; Ramaswamy Govindan; Fred R Hirsch; Gregory J Riely; Vassiliki Papadimitrakopoulou; Dickran Kazandjian; Sean Khozin; Erin Larkins; Dane J Dickson; Shakun Malik; Leora Horn; Andrea Ferris; Alice T Shaw; Pasi A Jänne; Tony S K Mok; Roy Herbst; Patricia Keegan; Richard Pazdur; Gideon M Blumenthal
Journal:  J Thorac Oncol       Date:  2016-07-09       Impact factor: 15.609

8.  Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.

Authors:  Lynne Penberthy; Richard Brown; Maureen Wilson-Genderson; Bassam Dahman; Gordon Ginder; Laura A Siminoff
Journal:  Clin Trials       Date:  2012-10-02       Impact factor: 2.486

9.  Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study.

Authors:  Linda Fleisher; Dominique G Ruggieri; Suzanne M Miller; Sharon Manne; Terrance Albrecht; Joanne Buzaglo; Michael A Collins; Michael Katz; Tyler G Kinzy; Tasnuva Liu; Cheri Manning; Ellen Specker Charap; Jennifer Millard; Dawn M Miller; David Poole; Stephanie Raivitch; Nancy Roach; Eric A Ross; Neal J Meropol
Journal:  Patient Educ Couns       Date:  2014-04-21

10.  Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.

Authors:  Filipa Lynce; Matthew J Blackburn; Ling Cai; Heping Wang; Larry Rubinstein; Pamela Harris; Claudine Isaacs; Paula R Pohlmann
Journal:  Breast Cancer Res Treat       Date:  2017-11-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.